BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BioCentury | Dec 11, 2018
Preclinical News

Anti-CD47 gel prevents cancer recurrence after surgery

ZenCapsule Inc. (Los Angeles, Calif.) is developing a localized sprayable gel similar to an anti-CD47 immunotherapeutic gel described in a new paper from University of California Los Angeles researchers that prevented postsurgical cancer recurrence in...
BioCentury | Apr 11, 2018
Preclinical News

Anti-inflammatories may prevent breast cancer recurrence

A Science Translational Medicine study from the Whitehead Institute for Biomedical Research suggests treating breast cancer patients with anti-inflammatory medication after tumor resection may prevent disease recurrence. The study was led by Robert Weinberg, co-founder...
BioCentury | Aug 24, 2009
Politics, Policy & Law

Deconstructing MDx Patents

Three upcoming court cases could render many molecular diagnostic patent claims moot, while narrowing the scope of claims inventors may seek in the future. While some MDx players and academic institutions worry that investors will...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

Italian and U.S. researchers have proposed treating epileptic seizures by targeting an inflammatory pathway outside the blood-brain barrier: leukocyte migration and recruitment. 1 The strategy potentially could help patients whose seizures are not adequately controlled...
BioCentury | Apr 7, 2008
Company News

Incitive, Peter MacCallum Cancer Institute deal

...40% of commercial revenue from the technology during the next five years and 20% thereafter. Incitive...
...failed to hit milestones, including delivery of small molecule inhibitors in an undisclosed time frame. Incitive...
...purified protease isolated from bromelain has completed preclinical testing to treat inflammatory bowel disease (IBD). Incitive Ltd....
BioCentury | Mar 24, 2008
Company News

Incitive board of directors update

Incitive Ltd. (ASX:ICV), Perth, Australia Business: Inflammation, Autoimmune Appointed: J.J. Kim Wright, former SVP of chemistry and preclinical development at ChemoCentryx Inc. Retired: Patty Washer WIR Staff...
BioCentury | Mar 17, 2008
Clinical News

Incitive preclinical data

...protease isolated from bromelain, which blocks the MAP kinase pathway to inhibit T cell activation. Incitive Ltd....
BioCentury | Mar 17, 2008
Clinical News

Incitive preclinical data

...protease isolated from bromelain, which blocks the MAP kinase pathway to inhibit T cell activation. Incitive Ltd....
BioCentury | Oct 15, 2007
Company News

Incitive board of directors update

Incitive Ltd. (ASX:ICV), Perth, Australia Business: Autoimmune, Inflammation Appointed: Mel Bridges, chairman of Alchemia Ltd. and ImpediMed Ltd., as chairman; and CEO Donald Home; Bridges replaces Sam Willis, who retired Retired: Tracey Mynott WIR Staff...
Items per page:
1 - 10 of 22
BioCentury | Jan 18, 2020
Product Development

Charting a course to intercepting Type I diabetes

Arguably, the most important innovations on the horizon for Type I diabetes would replace the insulin-producing cells patients have lost or prevent at-risk individuals from losing the cells in the first place. With Provention planning...
BioCentury | Dec 11, 2018
Preclinical News

Anti-CD47 gel prevents cancer recurrence after surgery

ZenCapsule Inc. (Los Angeles, Calif.) is developing a localized sprayable gel similar to an anti-CD47 immunotherapeutic gel described in a new paper from University of California Los Angeles researchers that prevented postsurgical cancer recurrence in...
BioCentury | Apr 11, 2018
Preclinical News

Anti-inflammatories may prevent breast cancer recurrence

A Science Translational Medicine study from the Whitehead Institute for Biomedical Research suggests treating breast cancer patients with anti-inflammatory medication after tumor resection may prevent disease recurrence. The study was led by Robert Weinberg, co-founder...
BioCentury | Aug 24, 2009
Politics, Policy & Law

Deconstructing MDx Patents

Three upcoming court cases could render many molecular diagnostic patent claims moot, while narrowing the scope of claims inventors may seek in the future. While some MDx players and academic institutions worry that investors will...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

Italian and U.S. researchers have proposed treating epileptic seizures by targeting an inflammatory pathway outside the blood-brain barrier: leukocyte migration and recruitment. 1 The strategy potentially could help patients whose seizures are not adequately controlled...
BioCentury | Apr 7, 2008
Company News

Incitive, Peter MacCallum Cancer Institute deal

...40% of commercial revenue from the technology during the next five years and 20% thereafter. Incitive...
...failed to hit milestones, including delivery of small molecule inhibitors in an undisclosed time frame. Incitive...
...purified protease isolated from bromelain has completed preclinical testing to treat inflammatory bowel disease (IBD). Incitive Ltd....
BioCentury | Mar 24, 2008
Company News

Incitive board of directors update

Incitive Ltd. (ASX:ICV), Perth, Australia Business: Inflammation, Autoimmune Appointed: J.J. Kim Wright, former SVP of chemistry and preclinical development at ChemoCentryx Inc. Retired: Patty Washer WIR Staff...
BioCentury | Mar 17, 2008
Clinical News

Incitive preclinical data

...protease isolated from bromelain, which blocks the MAP kinase pathway to inhibit T cell activation. Incitive Ltd....
BioCentury | Mar 17, 2008
Clinical News

Incitive preclinical data

...protease isolated from bromelain, which blocks the MAP kinase pathway to inhibit T cell activation. Incitive Ltd....
BioCentury | Oct 15, 2007
Company News

Incitive board of directors update

Incitive Ltd. (ASX:ICV), Perth, Australia Business: Autoimmune, Inflammation Appointed: Mel Bridges, chairman of Alchemia Ltd. and ImpediMed Ltd., as chairman; and CEO Donald Home; Bridges replaces Sam Willis, who retired Retired: Tracey Mynott WIR Staff...
Items per page:
1 - 10 of 22